single10MG
MOTS-C
10MG Protocol
MOTS-C 10MG
Injection Freq.
Inject once daily
Cycle Sched.
8–12 weeks; optional extension to 16 weeks
Reconstitution
3.0 mL BAC water
Improved insulin sensitivity and glucose metabolism in animal models
Reduced obesity/visceral fat through increased energy expenditure and fat oxidation
Improved exercise capacity and reduced age-related frailty signals in mice
Organ-protection signals (liver fat, cardiac function
preliminary cognitive signals)
Bone and immune-aging modulation signals in preclinical models
1
Reconstitution Requirements
- 3.0 mL BAC water
| Step | Week Range | Dose | Units |
|---|---|---|---|
| 1 | Weeks 1–2 | 200 mcg (0.2 mg) | 6 |
| 2 | Weeks 3–4 | 400 mcg (0.4 mg) | 12 |
| 3 | Weeks 5–6 | 600 mcg (0.6 mg) | 18 |
| 4 | Weeks 7–8 | 800 mcg (0.8 mg) | 24 |
| 5 | Weeks 9+ | 1,000 mcg (1.0 mg) | 30 |
Inject once daily
8–12 weeks; optional extension to 16 weeks
The MOTS-C protocol describes a mechanism that mimics aspects of exercise and cellular energy stress. MOTS-C is presented as activating AMPK primarily by inhibiting the folate cycle, which leads to accumulation of AICAR (an AMP analog) and turns on AMPK-driven metabolic programs. Once AMPK is activated, cells shift toward higher glucose uptake, increased fatty-acid oxidation, and improved mitochondrial respiration while downregulating fat storage and gluconeogenesis. The page also describes a second layer of biology: under stress conditions, MOTS-C can move into the nucleus and increase expression of antioxidant and stress-response genes, supporting cellular resilience. Additional pathways mentioned include possible modulation of mTOR and inflammatory signaling, which is linked to healthspan/lifespan interest in preclinical literature. The protocol repeatedly notes that benefits and safety are primarily inferred from animal studies; while a modified analog (CB4211) is noted as tolerable in early human research, MOTS-C itself lacks completed large human trials.
No specific adverse effects reported in preclinical studies (per page)
Human tolerability unknown (MOTS-C itself)
Injection-site reactions are possible with subcutaneous administration
- Use aseptic technique: wipe vial stopper with alcohol; use new sterile syringe/needle
- Add diluent slowly down the vial wall to minimize foaming
- Gently swirl/roll until fully dissolved (do not shake)
- Label vial with reconstitution date and concentration; protect from light
- Refrigerate after reconstitution (commonly 2–8 °C) unless protocol states otherwise
- Avoid repeated freeze–thaw cycles
- Bacteriostatic Water for Injection contains benzyl alcohol preservative (multi-dose); follow protocol for beyond-use (many peptide protocols use ~28 days after mixing)
- Avoid benzyl-alcohol-containing diluents in neonates/infants (safety warning for benzyl alcohol)